B-cell lymphoma clinical trials now open on the TrialWire Platform Jan 05, 2022 17:10 HKT | |
|
Autism clinical trials now open on the TrialWire Platform Jan 05, 2022 17:00 HKT | |
|
冠科美博(Apollomics)首席执行官余国良博士当选为百华协会 (BayHelix Group) 董事会主席 Jan 04, 2022 10:12 HKT | |
|
冠科美博(Apollomics)首席執行官余國良博士當選為百華協會 (BayHelix Group) 董事會主席 Jan 04, 2022 10:11 HKT | |
|
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group Jan 04, 2022 10:10 HKT | |
|
冠科美博(Apollomics)Uproleselan 注射液(APL-106)用于治疗复发或难治性急性髓系白血病的中国 III 期临床试验第一例受试者成功入组 Nov 22, 2021 10:42 HKT | |
|
冠科美博(Apollomics)Uproleselan 注射液(APL-106)用於治療復發或難治性急性髓系白血病的中國 III 期臨床試驗第一例受試者成功入組 Nov 22, 2021 10:41 HKT | |
|
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia Nov 22, 2021 10:40 HKT | |
|
Olympus Launches Venture Capital Fund to Strengthen Medtech Leadership Nov 12, 2021 07:30 HKT | |
|
Agilex Biolabs Shares How to Select the Right Bioanalytical Tools for Immuno-oncology and Vaccines Studies - OCT Webinar Oct 19, 2021 15:00 HKT | |
|
Avance Clinical Client News: XWPharma Initiates First-in-Human Studies of XW10508, in Development for Fast-acting Relief of Treatment-Resistant Depression and Chronic Pain Oct 19, 2021 15:00 HKT | |
|
Avance Clinical临床试验合作申办方XWPharma正式开启其XW10508首次人类临床试验,研究快速缓解难治性抑郁症以及慢性疼痛疗法 Oct 19, 2021 15:00 HKT | |
|
Avance Clinical臨床試驗合作申辦方XWPharma正式開啟其XW10508首次人類臨床試驗,研究快速緩解難治性抑鬱症以及慢性疼痛療法 Oct 19, 2021 15:00 HKT | |
|
Topelia Australia 发起 2500 万美元的 A 轮融资,募集资金用于 COVID-19 ATT Ziverdox Oct 15, 2021 07:00 HKT | |
|
Topelia Australia 發起 2500 萬美元的 A 輪融資,募集資金用於 COVID-19 ATT Ziverdox Oct 15, 2021 07:00 HKT | |
|
Topelia Australia launches US$25M Series A call for COVID-19 ATT Ziverdox Oct 14, 2021 14:45 HKT | |
|
Edison Oncology and Apollomics Announce Treatment of First Patient by EO1001 (APL-122) in a Phase I/IIa Clinical Trial Oct 01, 2021 10:00 HKT | |
|
Edison Oncology和冠科美博(Apollomics)宣布EO1001(APL-122) I/IIa 期临床试验中首例患者接受治疗 Oct 01, 2021 10:00 HKT | |
|
Edison Oncology和冠科美博(Apollomics)宣布EO1001(APL-122) I/IIa 期臨床試驗中首例患者接受治療 Oct 01, 2021 10:00 HKT | |
|
애질렉스 바이오랩스, 사이트라인 어워드(Citeline Award)의 코로나19 백신 독성학 임상 전 연구 부문 최종 수상 후보로 선정 Sep 24, 2021 17:00 HKT | |
|